Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Kirloskar Oil Engines Q2 Surge: Profit Soars 27.4% Amid Strategic B2C Shake-up!

Industrial Goods/Services

|

Updated on 11 Nov 2025, 01:50 pm

Whalesbook Logo

Reviewed By

Akshat Lakshkar | Whalesbook News Team

Short Description:

Kirloskar Oil Engines Ltd reported a strong Q2 FY26 with net profit up 27.4% year-on-year to ₹162.46 crore and revenue growing 30% to ₹1,948.4 crore, primarily driven by its B2B segment. The company also announced a strategic restructuring, transferring its B2C operations to a subsidiary to sharpen focus on B2B growth and work towards a $2 billion revenue target by 2030.
Kirloskar Oil Engines Q2 Surge: Profit Soars 27.4% Amid Strategic B2C Shake-up!

▶

Stocks Mentioned:

Kirloskar Oil Engines Ltd

Detailed Coverage:

Kirloskar Oil Engines Ltd announced robust financial results for the quarter ended September 2025 (Q2 FY26). The company's net profit increased by 27.4% year-on-year, reaching ₹162.46 crore, up from ₹127.51 crore in the same period last year. Revenue saw a significant 30% jump to ₹1,948.4 crore from ₹1,498.6 crore, largely propelled by strong performance in the business-to-business (B2B) segment.

EBITDA rose by 28.5% year-on-year to ₹381.75 crore, with operating margins holding steady at 19.6%. The B2B segment, which includes engines, gensets, electric motors, and farm machinery, contributed ₹1,456.64 crore to revenue. Complementing these results, Kirloskar Oil Engines also announced a strategic restructuring on October 10th, transferring its business-to-consumer (B2C) operations to its wholly owned subsidiary, La-Gajjar Machineries Private Limited, via a slump sale. This move aims to enhance focus on the B2B segment and aligns with the company's long-term vision to achieve a $2 billion top line by 2030.

Impact: This news significantly impacts the Indian stock market by providing key financial performance indicators for a listed industrial company and signaling strategic direction. Investors will assess the earnings growth, margin stability, and the effectiveness of the restructuring in driving future profitability and achieving stated targets. The improved financial performance and strategic focus on the B2B segment are likely to be viewed positively by investors, potentially influencing the stock's valuation. The successful execution of the B2C divestment and continued B2B growth are crucial factors for future stock performance. Rating: 7/10.

Difficult Terms: * **B2B (Business-to-Business)**: Transactions and business conducted between two businesses, rather than between a business and an individual consumer. * **B2C (Business-to-Consumer)**: Transactions and business conducted directly between a business and individual consumers. * **EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization)**: A measure of a company's operating performance before accounting for interest, taxes, depreciation, and amortization expenses. * **YoY (Year-on-Year)**: A comparison of data from the current period to the same period in the previous year. * **Slump Sale**: A method of selling one or more units of a business for a lump sum, rather than selling individual assets. It often involves the transfer of a business undertaking as a going concern. * **FY26 (Fiscal Year 2026)**: The financial year ending in March 2026.


Healthcare/Biotech Sector

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

JB Pharma Q2 Profit SOARS 19%! Revenue Jumps 8.4%! Is This Your Next Big Investment?

JB Pharma Q2 Profit SOARS 19%! Revenue Jumps 8.4%! Is This Your Next Big Investment?

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Novo Nordisk SHOCKS India: Blockbuster Drug Wegovy Price SLASHED by 33% Amid Fierce Rivalry!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

JB Pharma Q2 Profit SOARS 19%! Revenue Jumps 8.4%! Is This Your Next Big Investment?

JB Pharma Q2 Profit SOARS 19%! Revenue Jumps 8.4%! Is This Your Next Big Investment?

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!


Commodities Sector

Hindustan Copper Q2 Profit Skyrockets 83% - Is This The Start Of A New Copper Boom?

Hindustan Copper Q2 Profit Skyrockets 83% - Is This The Start Of A New Copper Boom?

Gold ETFs EXPLODE: India's Gold Investment Crosses ₹1 Lakh Crore - Is This Your Next Big Opportunity?

Gold ETFs EXPLODE: India's Gold Investment Crosses ₹1 Lakh Crore - Is This Your Next Big Opportunity?

EID Parry Stuns Investors: Massive Standalone Loss Revealed Amidst Soaring Consolidated Profits!

EID Parry Stuns Investors: Massive Standalone Loss Revealed Amidst Soaring Consolidated Profits!

India's Gold Secret: Unlock $850 Billion and Rule Global Finance?

India's Gold Secret: Unlock $850 Billion and Rule Global Finance?

Gold & Silver Surge Continues? Expert Unveils 2025 Bull Run Secrets & Your Investment Strategy!

Gold & Silver Surge Continues? Expert Unveils 2025 Bull Run Secrets & Your Investment Strategy!

Hindustan Copper Q2 Profit Skyrockets 83% - Is This The Start Of A New Copper Boom?

Hindustan Copper Q2 Profit Skyrockets 83% - Is This The Start Of A New Copper Boom?

Gold ETFs EXPLODE: India's Gold Investment Crosses ₹1 Lakh Crore - Is This Your Next Big Opportunity?

Gold ETFs EXPLODE: India's Gold Investment Crosses ₹1 Lakh Crore - Is This Your Next Big Opportunity?

EID Parry Stuns Investors: Massive Standalone Loss Revealed Amidst Soaring Consolidated Profits!

EID Parry Stuns Investors: Massive Standalone Loss Revealed Amidst Soaring Consolidated Profits!

India's Gold Secret: Unlock $850 Billion and Rule Global Finance?

India's Gold Secret: Unlock $850 Billion and Rule Global Finance?

Gold & Silver Surge Continues? Expert Unveils 2025 Bull Run Secrets & Your Investment Strategy!

Gold & Silver Surge Continues? Expert Unveils 2025 Bull Run Secrets & Your Investment Strategy!